Advertisement


Mansoor Raza Mirza, MD, on Ovarian Cancer: Results From the ENGOT-OV16/NOVA Trial

2016 ESMO Congress

Advertisement

Mansoor Raza Mirza, MD, of Rigshospitalet, Copenhagen University Hospital, discusses phase III study findings on maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer. (Abstract LBA3)



Related Videos

Breast Cancer

Judith Balmaña, MD, PhD, on Metastatic Breast Cancer: Study Results on Lurbinectedin (Spanish Language Version)

Judith Balmaña, MD, PhD, of Vall d’Hebron University Hospital, discusses in Spanish the findings of a single-agent phase II trial on the antitumor activity of lurbinectedin in BRCA1/2-associated metastatic breast cancer patients. (Abstract 223O)

Breast Cancer

Shou-Ching Tang, MD, PhD, on Recurrent CNS Metastases in Breast Cancer: Study Results on a Novel Conjugate

Shou-Ching Tang, MD, PhD, of the Georgia Cancer Center, discusses findings on a novel peptide–paclitaxel conjugate that crosses the blood-brain barrier and shows activity in breast cancer patients with recurrent central nervous system metastases. (Abstract 324O)

Multiple Myeloma

Katja Weisel, MD, on Multiple Myeloma: Results of the CASTOR Study

Katja Weisel, MD, of the University of Tübingen, discusses study findings on daratumumab, bortezomib, and dexamethasone vs bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma. (Abstract 906O)

Colorectal Cancer

Heinz-Josef Lenz, MD, on Colon Cancer: Sidedness and Treatment Update

Heinz-Josef Lenz, MD, of the University of Southern California Norris Comprehensive Cancer Center, discusses the importance of tumor location, and its implications for treatment, in right-sided and left-sided metastatic colon cancer.

Gynecologic Cancers

Jung-min Lee, MD, on Ovarian Cancer: Study Results on Checkpoint Kinase Inhibitors

Jung-min Lee, MD, of the National Cancer Institute, discusses findings of a phase II study of the cell cycle checkpoint kinase inhibitors LY2606368 and prexasertib monomesylate monohydrate in sporadic high-grade serous and germline BRCA mutation-associated ovarian cancer. (Abstract 855O)

Advertisement

Advertisement




Advertisement